ClinicalTrials.gg
CompletedNCT01701752Updated Jul 29, 2013

Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults

A Phase 1 interventional study of FP-01.1 + Placebo and FP-01.1 + TIV in Influenza A, sponsored by Immune Targeting Systems Ltd. Completed. Open to participants aged 65 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-07-29.

Sponsored by Immune Targeting Systems Ltd · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
65 Years to 74 Years
Sex
All
01

Study summary

This study will evaluate the safety and immunogenicity of FP-01.1 and FP-01.1 reformulated with an adjuvant (FP-01.1-Adjuvant) in relatively healthy subjects 65 to 74 years of age, subjects that are more representative of the target population. Both formulations will be administered alone or concomitantly with the Trivalent Inactivated Influenza Virus (TIV) vaccine.

02

Conditions studied

  • Influenza A

Browse trials for

Keywords

  • Influenza A
03

In context

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

This study's enrollment of 120 is below the median of 227 across 1,957 interventional studies indexed under Influenza, Human.

Browse Influenza, Human studies →

Lead sponsor

Immune Targeting Systems Ltd is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 65 to 74 years inclusive at the time of consent
  • Female subjects will be (no menses for at least 2 years) and therefore of non-child bearing potential
  • Male subjects willing to comply with the applicable requirements of the protocol, e.g. must agree to refrain from fathering a child until after the safety follow up visit. Male subjects do not need to use contraception if their partner has been through the menopause, or has had a hysterectomy or bilateral oophorectomy. If a male subject's partner is of child bearing potential, male subjects must agree to use a barrier method (condom) as a method of birth control in addition to any contraceptive measures normally taken by his partner, until after the safety follow up visit.
  • Satisfactory medical assessment with no or relevant abnormalities in medical history, physical examination, vital signs, and laboratory evaluation (haematology \& biochemistry) as assessed by the Investigator in relation to the age of the patient.
  • An understanding, ability and willingness to fully comply with study procedures and restrictions
  • Ability to provide written, personally signed and dated to participate in the study.
  • The subject has a \< 35.

Exclusion criteria

Exclusion Criteria:

  • As a result of the medical screening process, the Principal Investigator or Co- Investigator considers the subject unfit for the study.
  • Women of
  • , uncontrolled, current, chronic or recurrent disease, as deemed by the Investigator, (e.g. cardiovascular, respiratory, endocrine, renal, liver, gastrointestinal, , immune suppression, or other conditions) that could affect the action, absorption or disposition of the IMP or could affect clinical or laboratory assessments.
  • Significant illness as judged by the Principal Investigator or Co-Investigator within 2 weeks of the first dose of IMP.
  • Subjects with a history of allergies or allergic conditions including anaphylactic reactions, asthmatics, hay fever, allergy to egg products and eczema sufferers requiring medication which in the opinion of the Principal Investigator or Co- Investigator will affect their participation in the study.
  • Subjects receiving medications that affect the immune system including systemic at a dose greater than 5mg and patients on chronic medications where the dose has not been stable for at least 3 months. Inhaled or topical steroids will be allowed.
  • Known or suspected intolerance or to the IMP, or closely related compounds or any of the stated ingredients.
  • Male subjects who consume more than 21 units of alcohol per week and female subjects who consume more than 14 units of alcohol per week.
  • A positive antibody screen, surface antigen, Hepatitis B core antibody, or antibody screen
  • Subjects who have significant scarring, tattoos, abrasions, cuts or infections, that in the opinion of the Investigator could interfere with evaluation of injection site local reactions, over the deltoid region of both arms as these will be the dose site.
  • Donation of blood or blood products (e.g. plasma, ) within 90 days prior to or intention to donate blood during the entire study.
  • Use of another medicinal product within 90 days prior to receiving the first dose of IMP or intention to enrol in another clinical study throughout the entire study including the follow up period.
  • Subject with suspected recent (≤6 months) experience of influenza-like illness (fever [>37.8ºC] and cough and/or sore throat > 2 days- in the absence of a known cause other than influenza)
  • Subjects who have received a flu vaccine in the last 6 months
  • Any clinically significant abnormalities, in the opinion of the Principal Investigator or Co-Investigator, on (ECGs)
  • In addition, for each subject, a completed medical history questionnaire will be taken as part of the consented study procedure.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    Group 1

    Day 1: FP-01.1 + Placebo ; Day 29: FP-01.1

    Biological: FP-01.1 + Placebo · Biological: FP-01.1

  • Active comparator
    Group 2

    Day 1: FP-01.1 + TIV ; Day 29: FP-01.1

    Biological: FP-01.1 + TIV · Biological: FP-01.1

  • Active comparator
    Group 3

    Day 1: FP-01.1-Adjuvant + Placebo ; Day 29: FP-01.1-Adjuvant

    Biological: FP-01.1-Adjuvant + Placebo · Biological: FP-01.1-Adjuvant

  • Active comparator
    Group 4

    Day 1: FP-01.1-Adjuvant + TIV ; Day 29: FP-01.1-Adjuvant

    Biological: FP-01.1-Adjuvant + TIV · Biological: FP-01.1-Adjuvant

  • Active comparator
    Group 5

    Day 1: Adjuvant + TIV ; Day 29: Placebo

    Biological: Adjuvant + TIV · Other: Placebo

  • Active comparator
    Group 6

    Day 1: Placebo + TIV ; Day 29: Placebo

    Biological: Placebo + TIV · Other: Placebo

Interventions

  • BiologicalFP-01.1 + Placebo
  • BiologicalFP-01.1 + TIV
  • BiologicalFP-01.1-Adjuvant + Placebo
  • BiologicalFP-01.1-Adjuvant + TIV
  • BiologicalAdjuvant + TIV

    Drug page: Adjuvant

  • BiologicalPlacebo + TIV
  • BiologicalFP-01.1
  • BiologicalFP-01.1-Adjuvant
  • OtherPlacebo
06

What researchers measure

Primary outcomes

  1. Number and proportion of subjects reporting solicited local reactions and severity of the local reactions

    Time frame: Day 1- 209

  2. To assess and compare the immunogenicity response between groups

    The immunogenicity of two different formulations of FP-01.1 after each vaccine injection in each treated group

    Time frame: Day 1- 209

  3. Number and proportion of subjects reporting unsolicited AEs and Serious Adverse Events (SAEs)

    Time frame: Day 1- 209

  4. Number and proportion of subjects with abnormal haematology, blood chemistry lab assessments

    Time frame: Day 1- 209

  5. Number and proportion of subjects with abnormal vital signs/ECG assessments

    Time frame: Day 1 - 209

Secondary outcomes

  1. Exploratory immunogenicity tests on samples obtained from subjects

    Time frame: Day 1 -209

  2. To assess the impact of FP-01.1 and FP-01.1-Adjuvant on the immune response to TIV

    Time frame: Day 1-209

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2012
First posted
Oct 5, 2012
Start
Sep 2012
Primary completionActual
Apr 2013
CompletionActual
Apr 2013
Last update
Jul 29, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01701752
Lead sponsor
Immune Targeting Systems Ltd
Responsible party
Sponsor
First posted
Oct 5, 2012
Start date
Sep 2012
Primary completion
Apr 2013
Completion
Apr 2013
Last update
Jul 29, 2013

Study contacts

Geert Leroux-Roels, Professor
principal investigator · Centre for Vaccinology, Ghent University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adjuvant

Start the discussion